Diagnostic value of a complete blood count in type 2 diabetes mellitus and comorbidities

Hevko, Uliana; Kozak, Kateryna; Krynytska, Іnna

doi:10.31688/abmu.2020.55.4.06

Cited by 6 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetes mellitus (DM) is a complex disease which has become one of the most serious public health problems based on its increasing incidence, devastating complications and even concerning the cost of antidiabetic therapy. Type 2 diabetes is the most common type of diabetes, accounting for around 90% of all diabetes cases [10,13,20,21]. It is a progressive disease that is treated with oral antidiabetic medicines, and in some cases even insulin therapy will be needed to achieve the target blood glucose levels.…”

Section: Introductionmentioning

confidence: 99%

Application of Response Surface Methodology to Optimize the Technology of Metformin Oral Dissolving Tablets

DEMCHUK¹

2022

FARMACIA

View full text Add to dashboard Cite

To improve the compliance of patients with type 2 diabetes there is a need to develop metformin oral dissolving tablets, which disintegrate and dissolve rapidly in the saliva. The aim of this study was to optimize the composition of metformin orodispersible tablets. The central composite design was used to establish the relation between independent variables, such as, quantity of MCC Burst, quantity of Neusillin US2, and dependent variables, such as, flowability, bulk density, tapped density, uniformity of weight, friability, tablet hardness, disintegration time, wetting time in order to obtain the optimal formulation using Response Surface Methodology. After generating the polynomial equations that relate the dependent and independent variables, the process was optimized for five responses. From the dissolution studies, it is confirmed that all formulations released more than 82% of the metformin within 3 min. It was found that the tablet containing 3% MCC Burst and 5% Neusillin US2 was a better formulation in terms of hardness (72 N), uniformity of weight (1.09%), friability (0.75%), rapid disintegration (33 sec) and drug release (95.0%) when compared with all other formulations. RezumatPentru a îmbunătăți complianța pacienților cu diabet zaharat de tip 2, este nevoie de a dezvolta comprimate cu metformin cu dizolvare orală, care se dezintegrează și se dizolvă rapid în salivă. Scopul acestui studiu a fost de a optimiza compoziția comprimatelor orodispersabile cu metformin. Am stabilit relația dintre variabile independente, cum ar fi, cantitatea de MCC Burst, cantitatea de Neusillin US2 și variabilele dependente, cum ar fi curgerea, densitatea în vrac, densitatea la tasare, uniformitatea masei, friabilitatea, rezistența la rupere a comprimatelor, timpul de dezintegrare, timpul de umectare pentru a obține formularea optimă folosind metodologia suprafeței de răspuns. După generarea ecuațiilor polinomiale care leagă variabilele dependente și independente, procesul a fost optimizat pentru cinci răspunsuri. Studiile de dizolvare confirmă că toate formulările au eliberat mai mult de 82% din metformin în 3 minute. S-a constatat că tabletele care conțin 3% MCC Burst și 5% Neusillin US2 au prezentat o formulare mai bună în ceea ce privește duritatea (72 N), uniformitatea masei (1,09%), friabilitatea (0,75%), dezintegrarea rapidă (33 sec) și eliberarea substanței active (95,0%) în comparație cu toate celelalte formulări evaluate.

show abstract

Section: Introductionmentioning

confidence: 99%

Application of Response Surface Methodology to Optimize the Technology of Metformin Oral Dissolving Tablets

DEMCHUK¹

2022

FARMACIA

View full text Add to dashboard Cite

show abstract

“…In particular, this group of cytokines can disrupt insulin action in skeletal muscle, liver, brain, and other organs ( 11 ). Another disorder associated with obesity, IR and T2DM is chronic pancreatitis (CP) ( 12 ). Zhuravleva L.V.…”

Section: Introductionmentioning

confidence: 99%

Insulin Receptor Substrate 1 Gene and Glucose Metabolism Characteristics in Type 2 Diabetes Mellitus with Comorbidities

Mariya Marushchak,

Inna Krynytska

2021

Ethiop J Health Sci

View full text Add to dashboard Cite

BACKGROUND፡ Genetic variants that affect insulin signaling play an important role in insulin resistance (IR) in type 2 diabetes mellitus (T2DM). This study aimed to evaluate changes of the glycemic profile and IR in T2DM with comorbid obesity and chronic pancreatitis (CP) considering the allele status of the IRS1 gene (rs2943640).METHODS: The study involved 33 type-2 diabetic patients and 10 healthy individuals. The IRS-1 gene rs2943640 C>A polymorphism was genotyped using the TaqMan real-time PCR method.RESULTS: In type 2 diabetic patients regardless of the presence/absence of comorbid obesity and CP glycemic profile parameters significantly did not differ between carriers of allele С or allele A of the IRS1 gene (rs2943640). At the same time significantly higher HOMA-IR (by 2.25 times) was established in carriers of the C allele. In type 2 diabetic patients with both comorbidities (carriers of the C allele) the maximum HOMA-IR was established, which significantly differed from the data of patients with only T2DM and patients with comorbid obesity. In carriers of the A allele significantly higher level of HOMA-IR was found in patients with comorbid obesity and CP vs patients with only T2DM, and also in patients with comorbid obesity vs patients with only T2DM.CONCLUSIONS: Presence of the C allele of the IRS1 gene (rs2943640) may indicate risk of high IR in type 2 diabetic patients regardless of the presence/absence of comorbid obesity and CP; here with CP is a more important factor in IR progression then obesity.

show abstract

“…Insulin resistance (IR) plays a key role in the development of T2DM. This pathophysiological trait is also associated with other metabolic disorders including overweight, obesity, dyslipidemia, and hypertension (Sydorchuk et al 2017;Dworzynski et al 2020;Hevko et al 2020). Additionally, T2DM is linked to obesity by other pathophysiological factors, such as adipose tissue deregulation and excessive abdominal fat.…”

mentioning

confidence: 99%

Insulin receptor substrate-1 gene polymorphism and lipid panel data in type 2 diabetic patients with comorbid obesity and/or essential hypertension

Mazur

Krynytska

2023

Endocrine Regulations

Self Cite

View full text Add to dashboard Cite

Objective. The hallmarks of type 2 diabetes mellitus (T2DM) are insulin resistance (IR) and insulin receptor substrate (IRS) proteins essential for the insulin signaling. IRS-1 gene has not only been shown to be associated with T2DM, but also has indicated that it may significantly correlate with diabetic complications, such as coronary heart disease and obesity. The aim of this study was to evaluate changes of the lipid panel data in T2DM patients with comorbid obesity and/or essential hypertension in connection with the IRS-1 (rs2943640) polymorphism. Methods. The study involved 33 T2DM patients and 10 healthy individuals. The IRS-1 (rs2943640) polymorphism was genotyped using a TaqMan real-time polymerase chain reaction method. Blood serum lipid panel data were determined with commercially available kits using a Cobas 6000 analyzer. Results. Analysis of the serum lipid panel data depending on the presence of the C/A alleles of IRS-1 (rs2943640) polymorphism in T2DM patients, regardless of the presence/absence of comorbidities, showed significantly lower level of high-density lipoprotein cholesterol (HDL-C) and significantly higher level of non-HDL-C in the carriers of C allele vs. carriers of A allele. In T2DM patients with comorbid obesity and essential hypertension, proatherogenic lipid changes were found in both C and A alleles carriers. Analysis of the effect of IRS-1 (rs2943640) genotypes on serum lipid panel data in T2DM patients, regardless of the presence/absence of comorbidities, showed that the CC genotype carriers had more pronounced pro-atherogenic changes vs. carriers of СА and АА genotypes. In the comorbid course of T2DM (both in combination with obesity and obesity and essential hypertension), pro-atherogenic changes were found in the carriers of the CA genotype of IRS-1 (rs2943640) polymorphism. Conclusions. The presence of the C allele of IRS-1 (rs2943640) polymorphism in both homo-zygous and heterozygous states indicates increased risk of pro-atherogenic changes in T2DM patients with comorbid obesity and/or essential hypertension.

show abstract

Diagnostic value of a complete blood count in type 2 diabetes mellitus and comorbidities

Cited by 6 publications

References 30 publications

Application of Response Surface Methodology to Optimize the Technology of Metformin Oral Dissolving Tablets

Application of Response Surface Methodology to Optimize the Technology of Metformin Oral Dissolving Tablets

Insulin Receptor Substrate 1 Gene and Glucose Metabolism Characteristics in Type 2 Diabetes Mellitus with Comorbidities

Insulin receptor substrate-1 gene polymorphism and lipid panel data in type 2 diabetic patients with comorbid obesity and/or essential hypertension

Contact Info

Product

Resources

About